MegaRobo Technologies, a Chinese start-up that uses artificial intelligence and robotics in life sciences research, has raised $300 million in a funding round led by Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital.
The six-year-old company is the latest start-up from the pharmaceutical industry to capitalize on a jump in investor interest in the sector after the COVID-19 pandemic.
Market research platform AlphaSense also raised $225 million on Wednesday in a funding round that valued it at $1.7 billion, while biotechnology firm Synthego earlier this year raised $200 million in a fundraise led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2.
Read more: Reuters
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.